Postprandial lipoprotein metabolism and atherosclerosis

Journal of Internal Medicine

Volumn 246, Issue 4, 1999, Pages 341-355

  Karpe, Fredrik ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Apolipoprotein B 100; Apolipoprotein B 48; Atherosclerosis; Triglyceride rich lipoproteins; TRL remnants; VLDL

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN E; CHOLESTEROL; CHYLOMICRON; LIPOPROTEIN; LIPOPROTEIN LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; BLOOD VESSEL WALL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FAT INTAKE; FEMALE; HUMAN; LIPID TRANSPORT; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REGULATORY MECHANISM; REVIEW;

APOLIPOPROTEINS B; ARTERIOSCLEROSIS; CHOLESTEROL, VLDL; CHYLOMICRONS; HUMANS; LIPOPROTEINS; MUSCLE, SMOOTH, VASCULAR; PARTICLE SIZE; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 0032852279     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00548.x     Document Type: Review

References (120)

1. 1 Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-85.
2. 2 Kane JP, Hardman DA, Paulus HE. Heterogeneity of apolipoprotein B. Isolation of a new species from human chylomicrons. Proc Natl J Acad Sci (USA) 1980; 77: 2465-9.
3. 3 Hamsten A, Karpe F. Triglycerides and coronary heart disease - has epidemiology given us the right answer? In: Betteridge DJ, ed. Lipids: Curren Perspective. London: Martin Dunitz, 1996; 43-68.
4. 4 Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J, A novel form of specific RNA processing produces apolipoprotein B-48 in intestine. Cell 1987; 50: 831-40.
5. 5 Chen S-H, Habib G, Yang C-H et al. Apolipoprotein B-48 is the product of messenger RNA with an organ-specific inframe stop codon. Science 1987; 238: 363-6.
6. 6 Hayashi H, Fujimoto K, Cardelli JA. Nutting DF, Bergstedt S, Tso P. Fat feeding increases size, but not number of, chylomicrons produced by small intestine. Am J Physiol 1990; 259: G709-19.
7. 7 Martins IJ, Sainsbury AJ, Mamo JCL, Redgrave TG. Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron-like emulsions in insulin-deficient rats. Diabetologia 1994; 37: 238-46.
8. 8 Fielding BA, Callow J, Owen RM, Samra JS, Matthews DR, Frayn KN. Postprandial lipemia - the origin of an early peak studied by specific dietary fatty acid intake during sequential meals. Am J Clin Nutr 1996; 63: 36-41.
9. 9 Tso P, Drake DS, Black DD, Sabesin SM. Evidence for separate pathways of chylomicron and very low density assembly and transport by rat small intestine. Am J Physiol 1984; 247: G559-610.
10. 10 Semb H, Olivecrona T. Nutritional regulation of lipoprotein lipase in guinea pig tissue. Biochim Biophys Acta 1986; 876: 249-55.
11. 11 Ong JM. Kern PA. Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. J Clin Invest 1989; 84: 305-11.
12. 12 Frayn KN, Shadid S, Hamlani R et al. Regulation of fatty acid movement in human adipose tissue in the postabsorbtive-to-postprandial transition. Am J Physiol 1994; 266: E308-17.
13. 13 Malmström R, Packard CJ, Watson TD et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997; 17: 1454-64.
14. 14 Watts GF, Naoumova R, Cummings MH et al. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects. Metabolism 1995; 44: 1052-7.
15. 15 Malmström R, Packard CJ, Caslake M et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40: 454-62.
16. 16 Karpe F, Hellénius M-L, Hamsten A. Differences in postprandial concentrations of very low density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary artery disease. Metabolism 1999; 48: 301-7.
17. 17 Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. Arterioscler Thromb Vasc Biol 1995; 15: 2122-9.
18. 18 Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982; 31: 217-25.
19. 19 Fraze E. Bonner CC, Swislocki AL, Chiou YA, Chen YD, Reaven GM. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistante. J Clin Endocrinol Metab 1985; 61: 807-11.
20. 20 Chen YD, Golay A, Swislocki AL, Reaven GM. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 17-21.
21. 21 Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991; 72: 96-107.
22. 22 Chen YD, Swami S, Skrowronski R, Coulston AM, Reaven GM. Differences in postprandial lipemia between patients with normal glucose tolerance and non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 76: 172-7.
23. 23 Brunzell JD, Hazzard WR, Porte D, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man J Clin Invest 1973; 52: 1578-85.
24. 24 Björkegren J. Packard CJ, Hamsten A et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J lipid Res 1996; 37: 76-86.
25. 25 Chen YD, Coulston AM, Zhou MY, Hollenbeck CB, Reaven GM. Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM? Diab Care 1995; 18: 10-16.
26. 26 Patsch J, Postprandial lipaemia. Baillière's Clin Endocrinol Metabolism 1987; 1: 551-80.
27. 27 Grundy SM, Mok MYT. Chylomicron clearance in normal and hyperlipoproteinemic subjects. Metabolism 1976; 25: 1225-19.
28. 28 Lichtenstein AH, Hachey DL, Millar JS et al. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using (5, 5,5-2H3) leucine. J Lipid Res 1992; 33: 907-14.
29. 29 Karpe F, Olivecrona T, Hamsten A, Hultin M. Chylomicron/ chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J Lipid Res 1997; 38: 949-61.
30. 30 Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988; 29: 925-36.
31. 31 Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 1993; 91: 748-58.
32. 32 Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationship between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci (USA) 1993; 90: 2069-73.
33. 33 Karpe F, Hultin M. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicro-like triglyceride emulsion for a common lipolytic pathway. J Lipid Res 1995; 36: 1557-66.
34. 34 Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994; 5: 102-9.
35. 35 Cohn JS, Johnson EJ, Millar JS et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993; 34: 2033-40.
36. 36 Shachter NS, Ebara T, Ramakrishnan R et al. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest 1996; 98: 846-55.
37. 37 Shachter NS, Hayek T, Leff T et al. Overexpression of apolipoprotein C-II causes hypertriglyceridemia in transgenic mice. J Clin Invest 1994; 92: 1683-90.
38. 38 Aalto-Setälä K, Fisher EA, Chen X et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional cataholic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992; 90: 1889-900.
39. 39 deSilva HV, Lauer SJ, Wang J et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess upolipoprotein E. J Clin Invest 1994; 269: 2324-35.
40. 40 Agnani G, Bard J-M, Candelier L, Delattre L, Fruchart J-C, Clavey V. Interaction of LpB, LpB: E, LpB: C-III, and LpB: C-III lipoproteins with the low density lipoprotein receptor in HeLa cells. Arterioscler Thromb 1991: 11: 1021-9.
41. 41 Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J Biol Chem 1991; 265: 22453-9.
42. 42 Jong MC, Dahlmans VE, van Corp PJ et al. In the absence of the low density lipoprotein receptor, human apolipoprotein CI overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest 1996; 98: 2259-67.
43. 43 Björkegren J, Hamsten A, Milne RW, Karpe F. Alterations of VLDL composition during alimentary lipemia. J Lipid Res 1997; 38: 301-14.
44. 44 Björkegren J, Karpe F, Milne RW, Hamsten A. Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J Lipid Res 1998; 39: 1412-20.
45. 45 Nakajima K, Saito T, Tamura A et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993; 223: 53-71.
46. 46 Nakajima K, Okazaki M, Tanaka A et al. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apo B and apo A-I. J Clin Ligand Ass 1996; 19: 177-83.
47. 47 Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33: 369-80.
48. 48 Hazzard WR, Bierman EL. Delayed clearance of chylomicron remnants following vitamin-A-containing oral fat loads in broad-β disease (Type III hyperlipoproteinemia). Metabolism 1976; 25: 777-801.
49. 49 Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apoE. Science 1992; 258: 468-71.
50. 50 Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E deficient mire created by homologous recombinants in ES cells. Cell 1992; 71: 343-53.
51. 51 Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse apoE with human apoE2. J Clin Invest 1998; 102: 130-35.
52. 52 Huang Y, Liu XQ, Rall SC, Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem 1998; 273: 17483-90.
53. 53 Bergeron N, Havel RJ. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele. J Clin Invest 1996; 97: 65-72.
54. 54 Demant T, Bedford D, Packard CJ. Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipidemic subjects. J Clin Invest 1991; 88: 1490-501.
55. 55 Gaw A, Packard CJ, Lindsay GM et al. Overproduction of small very low density lipoproteins (Sf 20 60) in moderate hypercholesterolemia: relationship between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 1995; 36: 158-71.
56. 56 Rubinsztein DC, Cohen JC, Berger MC, Van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990; 86: 1306-12.
57. 57 Kita T, Goldstein JL, Brown MS, Watanabe Y, Hornick CA, Havel RJ. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci (USA) 1982: 79: 3623-7.
58. 58 Bowler A, Redgrave TG, Mamo JCL. Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidernic rabbits is defective. Biochem J 1991; 276: 381-6.
59. 59 Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in 'knockout' mice lacking the low density lipoprotein receptor, apolipoprotein E, or both. Proc. Natl Acad Sci (USA) 1994; 91: 4431-5.
60. 60 Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264: 1471-4.
61. 61 Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998; 101: 689-95.
62. 62 Windler E, Greeve J, Robenek H, Rinniger H, Greten H, Jäckle S. Differences in the mechanisms of uptake and endocytosis of small and large chylomicron remnants by rat liver. Hepatology 1996; 24: 344-51.
63. 63 Gianturco SH, Ramprasad MP, Sony R, Li R, Brown ML, Bradley WA. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol 1998; 18: 968-76.
64. 64 Lassel TS, Guérin M, Auboiron S, Chapman MJ, Guy-Grand B. Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects. Arterioscler Thromb Vasc Biol 1998; 18: 65-74.
65. 65 Wallentin L. Vikrot O. Influence of fat ingestion on lecithin: cholesterol acyltransfer rate in plasma or normal persons. Scand J Clin Lab Invest 1976; 36: 473-9.
66. 66 Rose HG, Juliano J. Regulation of plasma lecithin: cholesterol acyltransferase II. Activation during alimentary lipemia. J Lab Clin Med 1977; 89: 524-32.
67. 67 Tall AR, Blum CB, Forester GP, Nelson CA. Changes in the distribution and composition of plasma high density lipoproteins after ingestion of fat. J Biol Chem 1982; 257: 198-207.
68. 68 Tall AR, Summett D, Granot E. Mechanism of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia. J Clin Invest 1986; 77: 1163-72.
69. 69 Dullaart RPF, Groener JEM. van Wijk H, Sluiter WJ, Erkelens DW. Alimentary lipemia-induced redistribution of cholesterol ester between lipoproteins. Studies in normolipidemic, combined hyperlipidemic, and hypercholesterolemic men. Arteriosclerosis 1989; 9: 614-22.
70. 70 Karpe F, Bard J-M, Steiner G, Carlson LA, Fruchart J-C, Harnsten A. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at young age. Arterioscler Thromb 1993; 13: 11-22.
71. 71 Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991; 88: 2059-66.
72. 72 Ginsberg HN, Karmally W, Siddiqui M et al. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscler Thromb 1994; 14: 576-86.
73. 73 Dubois C, Armand M. Mekki N et al. Effects of increasing amounts of dietary cholesterol on postprandial lipemia and lipoproteins in human subjects. Am J Clin Nutrition 1994; 35: 1993-2007.
74. 74 Clifton PM, Nestel PJ. Effect of dietary cholesterol on postprandial lipoproteins in three phenotypic groups. Am J Clin Nutrition 1996; 64: 361-7.
75. 75 Dubois C, Armand M, Ferezou J et al. Postprandial appearance of dietary deuterated cholesterol in the chylomicron fraction and whole plasma in healthy subjects. Am J Clin Nutrition 1996; 64: 47-52.
76. 76 Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9: 471-4.
77. 77 Schumaker V, Phillips MC, Chatterton JE. Apolipoprotein B and low density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. Adv Prot Chem 1994; 45: 205-48.
78. 78 Le NA, Coates PM, Gallagher PR, Cortner JA. Kinetics of retinyl esters during postprandial lipemia in man: a compartmental model. Metabolism 1997; 46: 584-94.
79. 79 Karpe F, Humphreys SM, Samra JS, Summers LKM, Frayn KN. Clearance of lipoprotein remnant particles in adipose tissue and muscle in humans. J Lipid Res 1997; 38: 2335-41.
80. 80 Shaikh M, Wootton R. Nordestgaard B et al. Quantitative studies of transfer in vivo of low density, Sf 20-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991; 11: 569-77.
81. 81 Rapp JH, Lespine A, Hamilton RL. et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorbtion from human atherosclerotic plaque. Arterioscler Thromb 1994; 14: 1767-74.
82. 82 Borén J, Olin KL, Lee I, Chait A, Wight T, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL: a single point mutation in apolipoprotein B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998; 101: 2658-64.
83. 83 Veniant MM, Pierotti V, Newland D et al. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 1997; 100: 180-88.
84. 84 Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen actlvator inhibitor-1 gene implicated in the impaired fibrinolysis in hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18: 20-26.
85. 85 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-69.
86. 86 Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway, Arterioscler Thromb Vasc Biol 1996; 16: 1333-9.
87. 87 Sniderman AD, Cianflone K, Arner P, Summers LKM, Frayn KN. The adipocyte, fatty acid trapping and atherogenesis. Arterioscler Thromb Vasc Biol 1998; 18: 147-51.
88. 88 Hennig B, Shasby DM, Spector AA. Exposure of fatty acid increases human low density lipoprotein transfer across cultured endothelial monolayers. Circ Res 1985; 57: 776-80.
89. 89 Hennig B, Chung BH, Watkins BA, Alvarado A. Disruption of endothelial barrier function by lipolytic remnants of triglyceride-rich lipoproteins. Atherosclerosis 1992; 95: 235-47.
90. 90 Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96: 3266-8.
91. 91 Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997; 79: 350-54.
92. 92 Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997; 278: 1682-6.
93. 93 Simons LA, Dwyer T, Simons J et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987; 65: 181-9.
94. 94 Simpson HS, Willamson CM, Olivecrona T et al. Postprandial lipaemia, fenofibrate and coronary heart disease. Atherosclerosis 1990; 85: 653-62.
95. 95 Groot PHE, van Stiphout WAIIJ, Krauss XH et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary heart disease. Arterioscler Thromb 1991; 11: 653-62.
96. 96 Patsch JR, Miesenböck G, Hopferwieser T et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336-45.
97. 97 Uiterwaal CSPM, Grobbee DE, Witteman JCM et al. Postprandial triglyceride responses in young adult men and familial atherosclerosis. Ann Intern Med 1994; 121: 576-83.
98. 98 Katzel LI, Busby-Whitehead MJ, Rogus EM, Krauss RM, Goldberg AP. Reduced adipose tissue lipoprotein lipase responses, postprandial lipemia and low high-density lipoprotein-2 subspecies levels in older athletes with silent myocardial ischemia. Metabolism 1994; 43: 190-98.
99. 99 Nikkilä M, Solakivi T, Lehtimäki T. Koivula T, Laippala P, Åström B. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease. Atherosclerosis 1994; 106: 149-57.
100. 100 Hughes TA, Elam MB, Applegate WB et al. Postprandial lipoprotein responses in hypertriglyceridemic subjects with and without cardiovascular disease. Metabolism 1995; 44: 1082-98.
101. 101 Ginsberg HN, Jones J, Blaner WS et al. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol 1995; 15: 1829-38.
102. 102 Weintraub MS, Grosskopf I, Rassin T et al. Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: case control study over three years. Br Med J 1996; 312: 935-9.
103. 103 Syvänne M, Hilden H, Taskinen M-R. Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary heart disease. J Lipid Res 1994; 35: 15-26.
104. 104 Meyer E, Westerveld HT, de Ruyter-Meijstek FC et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996; 124: 221-35.
105. 105 Gronholdt ML, Nordestgaard BG, Nielsen TG, Sillesen H. Echoluscent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke 1996; 27: 2166-72.
106. 106 Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106: 83-97.
107. 107 Karpe F, de Faire U, Mercuri M, Bond MG, Hellénius M-L, Hamsten A. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis 1998; 141: 307-14.
108. 108 Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR III. Postprandial triglyceridemia and carotid atherosclerosis. Stroke 1992; 23: 823-8.
109. 109 Nestel PJ. Relationship between plasma triglycerides and removal of chylomicrons. J Clin Invest 1964; 43: 943-9.
110. 110 Gronholdt ML, Wiebe BM, Laursen H, Nielsen TG, Schroeder TV, Sillesen H. Lipid-rich carotid artery plaques appear echoluscent on ultrasound B-mode images and may be associated with intraplaque haemorrhage. Eur J Vasc Endovasc Surg 1997; 14: 439-5.
111. 111 Gronholdt ML, Nordestgaard BG, Wiebe BM, Wilhjelm JE, Sillesen H, Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation 1998; 97: 34-40.
112. 112 Karpe F, Bell M, Björkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 1995; 15: 199-207.
113. 113 Phillips ML, Pullinger C, Kroes I et al. A single copy of apolipoprotein B-48 is present on human chylomicron remnant. J Lipid Res 1997; 38: 1170-77.
114. 114 Karpe F, Tornvall P, Olivecrona T, Steiner G, Carlson LA, Hamsten A. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis 1993; 98: 33-49.
115. 115 Tornvall P, Båvenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993; 88: 2180-89.
116. 116 Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by anglography and clinical events. Circulation 1993; 88: 2762-70.
117. 117 Hodis HN, Mack WJ, Azen SP et al. Triglyceride-and cholesterol-rich lipoproteins have differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial on Lovastatin. Circulation 1994; 90: 42-9.
118. 118 Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997; 17: 715-22.
119. 119 Marcoux C, Tremblay M, Fredenrich A et al. Plasma remnant-like particle lipid apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis 1998; 139: 161-71.
120. 120 McNamara JR, Shah PK, Nakajima K et al. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin Chem 1998; 44: 1224-32.